The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Up to 40% of people with psoriasis have symptoms before they're 16 years old, and 10% get it before they're 10. Children can have mild, moderate, or severe psoriasis. It's a lifelong condition ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

She also mentioned how it connects to her past treatments for psoriasis ... If you could do some hair, you’ll never be broke,” Knowles said. “I told my kids that. My mama told me that.

affects up to half of psoriasis patients on the scalp, where the presence of hair can complicate topical treatment application. Scalp psoriasis often presents with persistent itch and discomfort ...

So if you’re also concerned about hair loss as well as psoriasis, this formula will help tackle both as it reduces the scalp inflammation too. Deliciously syrupy, the shampoo is based around the ...